Trial Profile
A Randomized, Double-blind, Placebo-controlled, Repeat Dose, 2-period Incomplete Block Crossover Safety and Pharmacokinetic Study of Umeclidinium in Adolescent Asthma Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 01 Sep 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Aug 2012 New trial record